
|Articles|November 17, 2014
NovoTTF and Temozolomide for Glioblastoma
Author(s)Steven A. Toms, MD
Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses the combination of the Novo Tumor Treating Fields (NovoTTF) system and temozolomide for patients with glioblastoma.
Advertisement
Clinical Pearls
Steven A. Toms, MD, director, neurosurgery, Geisinger Health System, discusses the combination of the Novo Tumor Treating Fields (NovoTTF) system and temozolomide for patients with glioblastoma.
- Patients were randomized 2:1 to NovoTTF in combination with temozolomide (n = 210) or standard therapy (n = 105), which included surgery, radiation, and temozolomide.
- Progression-free and overall survival were both enhanced with the addition of NovoTTF.
- Anecdotally, Toms said, NovoTTF has been well-tolerated by patients.
Read more about this novel therapy > >
<<<
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
3
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5




















